• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Two Robust Defensive Plays to Consider

In the healthcare sector, TMO and TEVA are well positioned to ride out the market's current volatility.
By BRET JENSEN
Oct 26, 2012 | 02:30 PM EDT
Stocks quotes in this article: TMO, TEVA

Market darlings Apple (AAPL) and Amazon (AMZN) both submitted quarterly earnings reports that disappointing investors and missed both top and bottom line estimates after the bell Thursday. In addition, Standard & Poor's (S&P) downgraded French banks this morning, which is likely adding to the volatility in the equity market.

Continuing yesterday's theme around adopting a defensive stance in allocating new money into equities for the moment, I have taken a hard look at the defensive stocks that serve the healthcare sector. Here are two companies that are well positioned in this stable industry, have cheap valuations and should be good places to ride out the current volatility in the overall market.

Thermo Fisher Scientific (TMO) provides analytical instruments, consumables and services for research, manufacture, analysis, discovery, and diagnostics.

Four reasons TMO is a solid, if unexciting, pick at $61 a share:  

  1. Consensus earnings estimates for both fiscal 2012 and fiscal 2013 have risen in the last month. More importantly, the company reported earnings and revenues that beat estimates this week. Its earnings per share (EPS) came in $0.06 a share above consensus and management raised guidance as well.
  2. TMO is seeing more positive comments in October from analysts. Oppenheimer initiated coverage on the shares with an Outperform rating earlier this month and RW Baird just upped its price target to $70 from $67 a share. Credit Suisse also just raised its price target to $71 from $65 a share, S&P followed by bumping its price target to $72 from $68 a share.
  3. The stock has a lower beta (0.79) than the overall market. It also sports a reasonable five-year projected PEG (1.11) for such a stable grower. The company made $1.77 a share in fiscal 2007 and is on track to make over $4.80 a share this fiscal year.
  4. The stock sells for 11.5x forward earnings and the majority of its sales are to the healthcare sector, which has less volatility in demand than other industries.

Teva Pharmaceutical (TEVA) is one of the largest generic drug makers in the world. It also sells branded drugs (Copaxone for multiple sclerosis is by far its largest contributor to revenue).

Four reasons TEVA is a value pick at under $41 a share:

  1. The company delivers steady earnings increases year-in and year-out. It made just under $5 a share in fiscal 2011 and is on track to earn more than $5.35 in fiscal 2013. Consensus EPS for fiscal 2013 is around $5.70 a share.
  2. The company provides a solid yield (2.1%), very low beta (0.34) and has more than doubled its revenues since fiscal 2007 both by organic growth and strategic acquisitions.
  3. The stock is trading at the very bottom of its five-year valuation range based on P/E, P/B, P/S and P/CF. TEVA trades for just over 7x times forward earnings.
  4. The median analysts' price target on TEVA -- held by the 22 analysts who cover the company -- is $49 a share. It also has a five-year projected PEG of under 1 (0.99).


Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long TEVA and AAPL and short AMZN.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login